Taipei, Dec. 20 (CNA) Taiwanese vaccine maker Adimmune Corp. will launch clinical trials for its COVID-19 vaccine candidate in Indonesia early next year, with initial results expected in mid-2022, as it seeks to tap into the Muslim market by obtaining halal certification, the company announced on Monday.
Adimmune Corp (國光生技) has an upbeat outlook for its flu vaccine business next year, chairman Steve Chan (詹啟賢) told a media briefing in Taipei yesterday.
The company expects to obtain marketing approval from the Chinese regulator for its quadrivalent flu vaccine in the first quarter of next year, with more approvals likely from regulators in Jordan and Pakistan later in the year, Chan said.
An application for market approval typically takes 12 to 18 months in those countries, Adimmune said.
Chan said he expects the company to receive orders for 5 million doses from China, which is a large market for flu vaccines.
Adimmune
Beverly Silver traces the growth of workers power in the auto industry and the resultant outsourcing of industry to lower wage areas of the globe, where workers organised again and fought for better conditions, effectively spreading a militant workers' movement across the globe.
Jeffrey Kopstein argues how the everyday resistance of East German workers could wear down a despotic state over four decades until it was eventually overthrown.